Skip to content

Agios Pharmaceuticals AGIO Treasury stock, shares (in shares)

Treasury stock, shares (in shares) at other companies

ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation

See full
Market cap$2.16B+18.1%
Enterprise value$2.08B+15.2%
P/S32.7×-16.7×

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%
Debt / equity0.0×
Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonShares.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's treasury stock, shares (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agios Pharmaceuticals's treasury stock, shares (in shares)?
Agios Pharmaceuticals (AGIO) reported treasury stock, shares (in shares) of $16.22M in Q1 2026.
How has Agios Pharmaceuticals's treasury stock, shares (in shares) changed year-over-year?
Agios Pharmaceuticals's treasury stock, shares (in shares) decreased by 0.0% year-over-year, from $16.22M to $16.22M.
What is the long-term trend for Agios Pharmaceuticals's treasury stock, shares (in shares)?
Over 3 years (2022 to 2025), Agios Pharmaceuticals's treasury stock, shares (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $16.22M to $16.22M.